Correction to: Roflumilast (Nature Reviews Drug Discovery, (2010), 9, 10, (761-762), 10.1038/nrd3276);Roflumilast

Nature Reviews Drug Discovery

Volumn 9, Issue 10, 2010, Pages 761-762

  Fabbri, Leonardo M ^a   Beghé, Bianca ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CORTICOSTEROID; FORMOTEROL FUMARATE; INDACATEROL; PHOSPHODIESTERASE IV; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE; TIOTROPIUM BROMIDE; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; HEADACHE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; ENZYMOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CYCLOPROPANES; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957606223     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/s41573-024-00960-1     Document Type: Erratum

References (21)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. [online],http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2= 1&intId=2180 (2009).
2. Barnes, P. J. Emerging pharmacotherapies for COPD. Chest 134, 1278-1286 (2008).
3. Lipworth, B. J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365, 167-275 (2005).
4. Hatzelmann, A. & Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297, 267-279 (2001).
5. Bundschuh, D. S. et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297, 280-290 (2001).
6. Martorana, P. A. et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 172, 848-853 (2005).
7. Grootendorst, D. C. et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62, 1081-1087 (2007).
8. European Medicines Agency (EMEA). European Public Assessment Report - Daxas. EMEA website [online], http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001179/WC500095209.pdf (2010).
9. Rabe, K. F. et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366, 563-571 (2005).
10. Calverley, P. M. et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176, 154-161 (2007).
11. Calverley, P. M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374, 685-694 (2009).
12. Fabbri, L. M. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374, 695-703 (2009).
13. Alverley, P. M. COPD: what is the unmet need? Br. J. Pharmacol. 155, 487-493 (2008).
14. Soriano, J. B. et al. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 374, 721-732 (2009).
15. Han, M. K. et al. COPD phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 182, 598-604 (2010).
16. Han, M. K. Medication adherence in COPD: what havewe learned? Thorax 64, 922-923 (2009).
17. Hurst, J. R. & Wedzicha, J. A. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med. 7, 40 (2009).
18. Wouters, E. F. et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naïve diabetes. Am. J. Respir. Crit. Care Med. 181, A4471 (2010).
19. IMS MIDAS (2009).
20. IMS Market Prognosis (2009).
21. Arnold, C. et al. Credit Suisse Equity Research Report (2 August 2010).